TABLE 2.
Immunoreactive regions on the 2008 GII.3 capsid protein
| Name | Amino acid positiona (domainb) and sequencec | No. of fixed amino acid mutationsd |
|---|---|---|
| IR-1 | aa 26–63 (S), AMALEPVAGAAIAAPLTGQQNIIDPWIMNNFVQAPGGE | 1 (E30D, Lin B/D) |
| IR-2 | aa 64–80 (S), FTVSPRNSPGEVLLNLE | 0 |
| IR-3 | aa 237–255 (P1), MSNSRFPVPIDSLHTSPTE | 0 |
| IR-4 | aa 362–379 (P2), AKVDTTSGRFTPKLGSLE | 3 (V364I, Lin E; S368A, Lin D; A372T, Lin B/C/D/E) |
| IR-5 | aa 380–405 (P2), ISTESDDFDQNKPTRFTPVGIGVDHE | 7 (S381T/I, Lin B/C; S385D/G, Lin D/E; S389P/T/Q, Lin B/C/D/E; Q391K, Lin E; P392S, Lin B/C; R394K, Lin B/C; N404H, Lin D/E) |
| IR-6 | aa 497–526 (P1), AKLHKLGFITIAKNGDSPITVPPNGYFRFE | 0 |
a
Amino acid position corresponds to sequence numbering of strain AU08.
b
Capsid protein structural domain. P2 is the most exposed.
c
Amino acid sequence of strain AU08.
d
The number of amino acid sites in the immunoreactive region containing a mutation that has become conserved over time with reference to the oldest GII.3 strain (DC2005, isolated in 1975). The mutation and the GII.3 lineages (Lin) within which a mutation has been conserved are listed in parentheses. Lineage A, strains from 1975 to 1983; lineage B, strains from the 1980s; lineage C, strains from the 1990s; lineage D, strains from 2001 to 2010; lineage E, strains from 2006 to 2010 (47).